Results 91 to 100 of about 2,341,910 (347)

Targeted Chemotherapy Using a Cytotoxic Somatostatin Conjugate to Inhibit Tumor Growth and Metastasis in Nude Mice

open access: yesClinical Medicine Insights: Oncology, 2008
The major problems of traditional chemotherapy are non-selectivity and non-specificity, resulting in severe toxic side effects. Peptides are a new-generation of drug-delivery vector to increase efficacy of this therapy and avoid the resulting damage. The
Li-Chun Sun   +4 more
doaj   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

open access: yesMolecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp   +13 more
wiley   +1 more source

Transcriptional co-activator regulates melanocyte differentiation and oncogenesis by integrating cAMP and MAPK/ERK pathways

open access: yesCell Reports, 2021
Summary: The cyclic AMP pathway promotes melanocyte differentiation by activating CREB and the cAMP-regulated transcription co-activators 1–3 (CRTC1–3). Differentiation is dysregulated in melanomas, although the contributions of CRTC proteins is unclear.
Jelena Ostojić   +6 more
doaj  

Peptide

open access: yes, 2001
Bibliography: p. 136-159.
openaire   +2 more sources

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

open access: yesMolecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche   +8 more
wiley   +1 more source

A DIA‐MS‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients

open access: yesMolecular Oncology, EarlyView.
A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy